Biogen Inc at Cowen Health Care Conference Transcript

Mar 06, 2023 / 02:50PM GMT
Philip M. Nadeau - Cowen and Company, LLC, Research Division - MD & Senior Research Analyst

Welcome to the TD Cowen 43rd Annual Healthcare Conference. I'm Phil Nadeau, one of the biotech analyst here at Cowen. It's my pleasure to moderate a fireside chat with Biogen. We're really happy to have with us today, Chris Viehbacher, the new CEO.

Chris, congratulations on assuming the role of CEO as BioCentury said this weekend, you have a tiger by the tail.

Questions and Answers:

Philip M. Nadeau - Cowen and Company, LLC, Research Division - MD & Senior Research Analyst

Maybe we'll start just with a general question. What's your view of the state of Biogen now? And what do you think Biogen needs to do over the next 5 years to create shareholder value?

Christopher A. Viehbacher - Biogen Inc. - President, CEO & Director

Well, thanks, Phil. It's good to be with you this morning. Biogen is in kind of two situations. On the one hand, we have the Biogen that has been successful over 45 years in multiple
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot